KRAS and neoplasm: Increasing evidence indicates that oncogenic drivers, including <i>EGFR</i>, <i>ALK</i>, <i>KRAS</i>, <i>MET</i>, <i>RET</i>, and <i>BRAF</i>, actively shape the tumor immune microenvironment (TIME) by regulating antigen presentation, immune cell infiltration, cytokine signaling, metabolic programs, and immune checkpoint expression.